Lantheus Holdings, Inc., as a director of Perspective Therapeutics, Inc. (ticker: CATX), sold 35,769 shares at $3.12 per share, totaling $111,574, on September 4, 2026. Who is Lantheus Holdings and What is Its Real Role in Perspective Therapeutics Lantheus Holdings, Inc. is a portfolio company that holds, among others, a management position within Perspective Therapeutics. As a director, Lantheus has voting rights and participates in the strategic decisions of the company, granting it direct access to non-public financial and operational information. This leadership role entails a fiduciary responsibility to Perspective Therapeutics' shareholders. Officers are required to uphold the transparency obligations imposed by the Securities and Exchange Commission (SEC), including reporting their transactions in the company's securities. Lantheus' role as a director means it can influence research directions, partnership agreements, and funding decisions, factors that can impact the company's valuation. Transaction Details: 35,769 shares at $3.12 each The Form 4 filed on September 4, 2026, indicates that Lantheus Holdings sold exactly 35,769 shares of Perspective Therapeutics. The per-share price was $3.12, resulting in a gross transaction value of $111,574. It is important to clearly distinguish between the per-share price and the total amount, two distinct figures presented in the form. The $3.12 price reflects the market price at the time of sale, while the $111,574 represents the actual amount received by the insider. This transaction was recorded in the insider transactions registry (Form 4) and made public within two business days of the sale date, complying with regulatory requirements. Why Insiders Sell Their Shares – Possible Reasons Leadership may decide to liquidate a portion of their shares for several reasons that are not necessarily related to the company's future performance. Portfolio diversification is a common motivation: holding an excessive number of shares in one company exposes the investor to concentrated risk. Tax considerations may also come into play, such as the need to realize capital gains at a favorable tax rate or to cover personal tax obligations. Personal liquidity needs, such as funding a real estate purchase or paying for an unexpected expense, can justify the sale of shares held by a director. Finally, the decision to sell may be perceived as a bearish signal by the market, but it is impossible to assert that the transaction reflects an expectation of a price decline. Personal and financial reasons often prevail. How Individual Investors Track Form 4s Forms 4 are freely accessible on the SEC's website via the EDGAR platform. Investors can search for the ticker CATX, then filter documents by form type to identify insider declarations. Online services, such as OpenInsider, WhaleWisdom, or the "Insider Transactions" section of Bloomberg, aggregate Form 4 data and offer visualization tools that simplify reading volumes and transaction prices. It is important to note, however, that information published in Form 4s is retrospective by two business days, creating a slight lag between transaction execution and public dissemination. Additionally, the form does not specify the exact motivations of the insider. Regulatory Context of Insider Declarations U.S. law requires every director, officer, or shareholder holding more than 10% of a listed company's capital to file a Form 4 each time they execute a buy or sell transaction in the company's shares. The filing must be made within two business days of the transaction. This requirement aims to ensure market transparency and prevent abuses of insider information. Failure to comply with the filing deadline exposes insiders to administrative sanctions and, in serious cases, to criminal proceedings. The form indicates the number of shares, the execution price, the transaction date, and the type of operation (purchase or sale). All this information is public and accessible to any investor. Interpreting Insider Sales with Caution When directors sell their shares, it is advisable for investors not to draw hasty conclusions about the stock's future trajectory. The sale may reflect liquidity needs, estate planning, or simply taking profits after a price increase. Analyzing insider sales should be complemented by other indicators, such as financial results, development pipeline prospects for a biopharmaceutical company like Perspective Therapeutics, and sector trends. By combining Form 4 data with an in-depth analysis of the company's fundamentals, individual investors can form a more balanced opinion and reduce the risk of decisions based on a single signal. Using Free Tools to Monitor Insider Movements In addition to the SEC's official website, several platforms offer email or mobile notifications as soon as a new Form 4 is published for a specific ticker. These services allow investors to stay informed in real-time without additional costs. Investors can create watchlists including CATX and other stocks of interest, then set filters to receive only transactions exceeding certain volume or price thresholds. It is essential to verify the source of each data point and ensure it originates from the official form, to avoid reporting errors from third-party sites that are not verified. In summary, the sale of 35,769 shares of Perspective Therapeutics by Lantheus Holdings, declared on September 4, 2026 via Form 4, represents a transaction of $111,574 at a price of $3.12 per share. The director role grants Lantheus privileged access to company information, but the reasons for the sale remain multiple and do not allow definitive conclusions about the future direction of the stock price. Individual investors have free tools to monitor these declarations, while keeping in mind the limitations of timing and interpretation inherent in insider data.